Adagene Inc.

Adagene Inc. is a clinical-stage biotechnology company focused on researching, developing, and producing monoclonal antibody drugs for cancers in the People's Republic of China. The company's lead product candidate is ADG126, a masked fully-human anti-CTLA-4 mAb, which is in phase 1b/2 clinical development for cancer treatment. Adagene also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, currently in phase 1b/2 clinical trials for advanced/metastatic solid tumors. Other product candidates include ADG206, in phase 1 clinical development for advanced metastatic solid tumors; ADG104, an anti-PD-L1 monoclonal antibody in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb in Phase 2 clinical development. Additionally, the company is developing ADG138, a HER2xCD3 POWERbody in preclinical trials for low expressing tumors and resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody in preclinical trials for off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody in preclinical trials for hematologic and solid tumors; and CD28 T-cell engagers, which are anti-CD28 bispecific POWERbody TCEs for solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.